Relapse of Experimental Autoimmune Encephalomyelitis after Discontinuation of FTY720 (Fingolimod) Treatment, but Not after Combination of FTY720 and Pathogenic Autoantigen

Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective

(2011) M. K. Racke et al.   JOURNAL OF IMMUNOLOGY

Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model

(2010) Sachi Tsunemi et al.   CLINICAL IMMUNOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

(2009) Dimitrios Papadopoulos et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Synthesis of the Key Intermediate, Diethyl 2-Acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3-dioate, of the Immunomodulatory Agent FTY720 (Fingolimod)

(2008) Norimasa Matsumoto et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY